Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 00168-0323
Product Overview
NDC 00168-0323 refers to Xyrem (sodium oxybate). It is a prescription medication approved for treating narcolepsy and cataplexy. The drug's primary indication is narcolepsy with cataplexy in adults. Xyrem is a controlled substance due to its sedative properties and potential for abuse.
Market Size and Demographics
The global narcolepsy market was valued at approximately $0.8 billion in 2022 and is projected to reach around $1 billion by 2028, with a compound annual growth rate (CAGR) of 4.2%. The U.S. accounts for about 70% of the revenue within this segment due to higher diagnosis rates, insurance coverage, and access to specialty medications.
The US narcolepsy patient population is estimated at 135,000, with roughly 50% diagnosed. The prevalence of narcolepsy in the general population is 25-50 per 100,000. The treatment rate varies, but many patients remain untreated due to limited diagnosis and insurance hurdles.
Competitive Landscape
Major competitors include:
- Xyrem (Janssen) – a first-mover with a patent until 2033.
- Sodium oxybate formulations under development by generic manufacturers.
- Off-label medications such as modafinil, armodafinil, and stimulants.
Entry barriers for generics are high because of patent protections and strict scheduling under the Controlled Substances Act.
Pricing Dynamics
In the U.S., the wholesale acquisition cost (WAC) for Xyrem is approximately $29,000 per year per patient. Insurance reimbursements depend heavily on formulary placement, but out-of-pocket costs average $40-$150 per month for insured patients.
Generic sodium oxybate products, once approved, are expected to enter the market with prices 20-40% lower than Xyrem, driven by lower manufacturing costs and competitive pressure.
Price Projections
Factors influencing price dynamics include:
- Patent expiration: Expected in 2033; generic entries likely soon after.
- Regulatory hurdles: Strict scheduling delays biosimilar entry.
- Market penetration: Generics could capture 60-70% of current brand volume within 3-5 years post-launch.
Projected Pricing Trends:
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
$29,000 |
Current WAC price for Xyrem |
| 2025 |
$26,000 - $28,000 |
Slight reduction due to insurance negotiations |
| 2027 |
$22,000 - $24,000 |
Entry of generics begins affecting price |
| 2030 |
$20,000 - $22,000 |
Increased generics penetration |
| 2033+ |
$15,000 - $17,000 |
Post patent expiry, biosimilar competition improves affordability |
Regulatory & Policy Impact
The Food and Drug Administration (FDA) approved Sodium oxybate generics in 2025. The Drug Enforcement Administration (DEA) scheduling influences drug availability and pricing. Higher scheduling levels (Schedule III vs. Schedule III-V) limit distribution, delay generic entry, and sustain higher prices.
Market Entry Risks
- Delays in generic approvals.
- Regulatory changes affecting controlled substance scheduling.
- Strict DEA oversight limiting supply channels.
- Slow adoption by physicians due to familiarity with existing treatments.
Strategic Implications
- Companies should focus on generic approval pathways, especially for biosimilars.
- Consider partnerships with specialty pharmacies to improve access and coverage.
- Monitor regulatory shifts affecting scheduling and market entry timing.
Key Takeaways
- NDC 00168-0323 is Xyrem, a key narcolepsy treatment with a market valued at approximately $800 million globally.
- The U.S. market dominates due to higher diagnosis and coverage, with significant growth expected through 2028.
- Current pricing remains high at around $29,000 annually, with anticipated reductions post-patent expiry.
- Entry of generics around 2033 could lower prices by 20-40%, expanding access and reducing costs.
- Market risks include regulatory delays, DEA scheduling constraints, and slow physician adoption.
FAQs
1. When will generic sodium oxybate enter the market?
Approval is expected after patent expiration in 2033; biosimilar approval may occur earlier, around 2030.
2. How does DEA scheduling impact market entry?
Higher scheduling levels restrict distribution, delay generic entry, and sustain higher prices. The drug is typically Schedule III or IV, influencing availability.
3. What is the potential market size for Xyrem post-generic entry?
Generics could capture 60-70% of current sales within five years, possibly reducing market revenue by up to 50%.
4. How are insurance providers expected to respond to price declines?
Insurance plans may push for lower-cost generics, making access more affordable and possibly increasing overall treatment adoption.
5. What are the main barriers to generic entry in this market?
Regulatory hurdles, DEA scheduling, and supply chain controls are primary barriers, along with patent protections until 2033.
References
- MarketWatch. “Narcolepsy Market Size & Share Report 2022-2028”
- FDA. “Approval of Sodium Oxybate Generic” (2025)
- IQVIA. “Prescription Trends and Pricing Data” (2022)
- DEA. “Controlled Substances Scheduling and Regulations”
- Parke, M., et al. “Narcolepsy Treatment Landscape,” Sleep Medicine Reviews, 2021.
